| pubmed-article:1155490 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1155490 | lifeskim:mentions | umls-concept:C0341697 | lld:lifeskim |
| pubmed-article:1155490 | lifeskim:mentions | umls-concept:C0040341 | lld:lifeskim |
| pubmed-article:1155490 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1155490 | pubmed:dateCreated | 1975-11-6 | lld:pubmed |
| pubmed-article:1155490 | pubmed:abstractText | Calculated elimination rate constants of tobramycin were correlated with endogenous creatinine clearances in 128 normal subjects or patients with various degrees of renal impairment. A similar correlation was made with serum creatinine concentration in 85 subjects. Superimposition of these regression lines permitted calculation of daily maintenance dosage ranges for tobramycin in patients with all degrees of impairment of renal function as determined by either creatinine clearances or serum creatinine concentrations. These maintenance dosage ranges are presented in a simplified figure. | lld:pubmed |
| pubmed-article:1155490 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1155490 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1155490 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1155490 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1155490 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1155490 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1155490 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1155490 | pubmed:issn | 0002-9629 | lld:pubmed |
| pubmed-article:1155490 | pubmed:author | pubmed-author:BlackH RHR | lld:pubmed |
| pubmed-article:1155490 | pubmed:author | pubmed-author:BechtolL DLD | lld:pubmed |
| pubmed-article:1155490 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1155490 | pubmed:volume | 269 | lld:pubmed |
| pubmed-article:1155490 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1155490 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1155490 | pubmed:pagination | 317-21 | lld:pubmed |
| pubmed-article:1155490 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1155490 | pubmed:meshHeading | pubmed-meshheading:1155490-... | lld:pubmed |
| pubmed-article:1155490 | pubmed:meshHeading | pubmed-meshheading:1155490-... | lld:pubmed |
| pubmed-article:1155490 | pubmed:meshHeading | pubmed-meshheading:1155490-... | lld:pubmed |
| pubmed-article:1155490 | pubmed:meshHeading | pubmed-meshheading:1155490-... | lld:pubmed |
| pubmed-article:1155490 | pubmed:meshHeading | pubmed-meshheading:1155490-... | lld:pubmed |
| pubmed-article:1155490 | pubmed:meshHeading | pubmed-meshheading:1155490-... | lld:pubmed |
| pubmed-article:1155490 | pubmed:meshHeading | pubmed-meshheading:1155490-... | lld:pubmed |
| pubmed-article:1155490 | pubmed:articleTitle | Tobramycin in renal impairment. | lld:pubmed |
| pubmed-article:1155490 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1155490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1155490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1155490 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1155490 | lld:pubmed |
